Three Distinct Clinical Phenotypes of Immunotherapy-Induced Bullous Pemphigoid Predict Divergent Treatment Responses and Outcomes

Figure S1: Nodular-erosive type:Figure Legend: Firm, dark brown to skin-colored nodules with characteristic surface ulcerations and crusting on the lower extremities.Figure S2: Therapeutic Approach Distribution Among ICI-BP SubtypesFigure Legend: This analysis reveals distinct treatment response profiles across ICI-BP subtypes. The bullous type showed optimal response to glucocorticoid monotherapy (80% of cases), while the edematous erythema-bullous type predominantly required combination regimens (55.6% GCs+MTX, 22.2% GCs+MTX+IVIG). The nodular-erosive type displayed an intermediate pattern, with 75% managed by GCs alone and 25% requiring GCs+MTX+IVIG. Abbreviation: Edematous erythema-bullous type, EEB type; methotrexate,MTX; GCs: Glucocorticoid; IVIG: Intravenous immunoglobulin; Figure S3(A). Initial Steroid Doses Across Clinical Subtypes (mg)Figure Legend: The analysis revealed significant differences in initial steroid requirements: spontaneous BP (30 mg), edematous erythema-bullous type (48 mg), nodular-erosive type (43 mg), and bullous type (30 mg).(B). Comparison of Initial Steroid Doses Between Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid and Spontaneous Bullous Pemphigoid.Figure Legend: The scatter plot demonstrates significantly higher initial steroid doses in immune-related BP (edematous erythema-bullous + nodular-erosive subtypes) versus spontaneous BP (mean methylprednisolone 40 mg vs 30 mg; P=0.0446). Abbreviation：Edematous erythema-bullous type, EEB typeTable S1. Baseline characteristics and key laboratory features (ICI-BP vs sBP)Table S2. Treatment regimens and outcomes by ICI-BP clinical phenotype versus sBP